Earlier initiation of caffeine may be associated with a greater reduction in time on ventilation.Additional members of the Caffeine for Apnea of Prematurity Trial Group are available at We use cookies to help provide and enhance our service and tailor content and ads. Findings This follow-up study to the Caffeine for Apnea of Prematurity trial found that the combined rate of academic, motor, and behavioral impairment at 11 years of age did not differ significantly between participants who had been randomly assigned to receive caffeine compared with those who had been randomly assigned to receive placebo. Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. We investigated the consistency of caffeine effects by using regression models that incorporated treatment/subgroup factor interactions.There was little evidence of a differential treatment effect of caffeine in subgroups defined by the clinical indication for starting study drug. Caffeine citrate has been approved by the Food and Drug Administration for treatment of apnea of prematurity, whereas theophylline has not. Caffeine for Apnea of Prematurity trial: benefits may vary in subgroups. N Engl J Med 2006; 354:2179. Long-term effects of caffeine therapy for apnea of prematurity. schmidt@mcmaster.ca Comment in N Engl J Med. Davis PG, Schmidt B, Roberts RS, et al. J Pediatr. Outcomes assessed were those showing treatment effects in the original analyses. Infants receiving respiratory support appeared to derive more neurodevelopmental benefits from caffeine than infants not receiving support. Lodha A, Seshia M, McMillan DD, et al. Apnea of prematurity affects more than half of preterm neonates. JAMA Pediatr 2015; 169:33. To determine whether the benefits of caffeine vary in three subgroups of 2006 participants in the Caffeine for Apnea of Prematurity (CAP) trial. 2010; 156(3):382-7 (ISSN: 1097-6833) Davis PG; Schmidt B; Roberts RS; Doyle LW; Asztalos E; Haslam R; Sinha S; Tin W; OBJECTIVE: To determine whether the benefits of caffeine vary in three subgroups of 2006 participants in the Caffeine for Apnea of Prematurity (CAP) trial. Association of early caffeine administration and neonatal outcomes in very preterm neonates. We investigated the consistency of caffeine effects by using regression models that incorporated treatment/subgroup factor interactions.There was little evidence of a differential treatment effect of caffeine in subgroups defined by the clinical indication for starting study drug. Bancalari E. Caffeine for apnea of prematurity. By continuing you agree to the Copyright © 2020 Elsevier B.V. or its licensors or contributors. Earlier initiation of caffeine may be associated with a greater reduction in time on ventilation.Additional members of the Caffeine for Apnea of Prematurity Trial Group are available at We use cookies to help provide and enhance our service and tailor content and ads. Herjua/Thinkstock . Study design. Schmidt B(1), Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, Solimano A, Tin W; Caffeine for Apnea of Prematurity Trial Group. The Caffeine for Apnea of Prematurity (CAP) trial compared short- and long-term outcomes of preterm infants treated with caffeine with those of infants receiving a placebo. 2007 Nov … Outcomes assessed were those showing treatment effects in the original analyses. ScienceDirect ® is a registered trademark of Elsevier B.V.Caffeine for Apnea of Prematurity Trial: Benefits May Vary in SubgroupsCanadian Institute of Health Research and the National Health and Medical Research CouncilScienceDirect ® is a registered trademark of Elsevier B.V. To determine whether the benefits of caffeine vary in three subgroups of 2006 participants in the Caffeine for Apnea of Prematurity (CAP) trial.Post-hoc subgroup analyses were performed on the basis of: (1) indication for commencement of study drug: treat apnea, prevent apnea, or facilitate extubation; (2) positive pressure ventilation (PPV) at randomization: endotracheal tube (ETT), noninvasive ventilation, or none; and (3) timing of commencement of study drug: early or late (≤3 versus >3 days). The size and direction of the caffeine effect on death or disability differed depending on PPV at randomization (There is evidence of variable beneficial effects of caffeine. Infants receiving respiratory support appeared to derive more neurodevelopmental benefits from caffeine than infants not receiving support. Author information: (1)Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON, Canada. The dosage used in the largest randomised controlled trial (RCT) conducted to date investigating caffeine in preterm infants, the Caffeine for Apnea of Prematurity (CAP) trial , is the most often quoted template for local caffeine therapy protocols. The size and direction of the caffeine effect on death or disability differed depending on PPV at randomization (There is evidence of variable beneficial effects of caffeine. By continuing you agree to the Copyright © 2020 Elsevier B.V. or its licensors or contributors. J Pediatr 2010; 156:382. Infants were eligible for inclusion when their clinicians considered them to be candidates for methylxanthine therapy during the first 10 days of life.1, 2.